Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. MSTR
5. MU
6. DFTX
7. BAUFF
8. ICE
9. KR
10. RGA

Go back to Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 26, 2024 7:03 AM EDT

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days

VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events

Phase 2 Trial in Obesity Planned for 2H24

Conference Call Scheduled for 8:00 a.m. ET Today

SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:... More